RALY and neoplasm: Independent of the exact mechanisms involved in oxaliplatin resistance, NONO and RALY are good potential targets for the sensitization of otherwise oxaliplatin resistant YB-1 overexpressing colorectal cancer tumor cells (Figure 10).